Peripheral T-cell lymphoma is an aggressive disease requiring chemotherapy that often includes the drugs cyclophosphamide, doxorubicin, vincristine, and prednisone (a regimen abbreviated as CHOP). After initial chemotherapy, patients are usually observed and not treated again unless the disease comes back or gets worse.
Since initial chemotherapy usually only works for a short time, researchers are seeking ways to delay or avoid a recurrence or progression of disease. Pralatrexate is a new drug that has been approved for the treatment of T-cell lymphoma after it has returned or worsened after chemotherapy. In this study, researchers want to see if giving pralatrexate after initial therapy is completed (before disease progression has occurred) can prevent or delay a recurrence of T-cell lymphoma.
Patients in this study will be randomly assigned to receive pralatrexate or undergo observation.